THERMAL SPEAKERS - Key Persons
Job Titles:
- Vice Chancellor of University of Global Health Equity. Former Minister of Health of Rwanda.
Job Titles:
- CEO and Chairman of Pfizer.
- Doctor of Veterinary Medicine
Albert Bourla is the CEO and Chairman of Pfizer, one of the world's premier innovative biopharmaceutical companies.
Prior to becoming CEO, Bourla served as the Chief Operating Officer, overseeing the company's commercial, strategy, manufacturing, and global product development. As the former Group President of Pfizer Innovative Health, he was responsible for the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, and Vaccines business groups, as well as for creating the Patient and Health Impact group that focused on developing solutions for increasing patient access and ensuring broader business model innovation. Bourla's other roles include Group President of Global Vaccines, Oncology, and Consumer Healthcare Business; President and General Manager of Established Products; and Area President of Pfizer Animal Health in Europe, Africa, Middle East, and Asia-Pacific regions.
Bourla currently serves on the Board of the Pfizer Foundation, which promotes access to quality health care, and the Executive Committee of Biotechnology Innovation Organization (BIO), the world's largest biotechnology trade association.
Bourla is a Doctor of Veterinary Medicine and holds a Ph.D. in the biotechnology of reproduction from the Veterinary School of Aristotle University. Prior to joining Pfizer in the animal health division, he was a practicing veterinarian in Greece.
Job Titles:
- CEO of the Personal Genetics Company 23andMe
- Co - Founder and CEO of 23andMe.
Anne Wojcicki is the cofounder and CEO of the personal genetics company 23andMe, a pioneering direct-to-consumer DNA testing firm.
Anne received a B.S. degree (1996) in biology from Yale University. She later worked as a researcher and as an investment analyst. In 2006, while pursuing her interest in the potential to influence health care through personal genetic testing, Wojcicki cofounded 23andMe with biologist Linda Avey. Wojcicki and Avey believed that individuals provided with personal knowledge of disease risk would be empowered and better prepared to take steps toward disease prevention.
In 2008 a retail saliva genetic test developed by researchers at 23andMe was named Time magazine's Invention of the Year. The test provided customers with information about their genetic traits, including estimates of their predisposition toward various health conditions. By 2016, researchers at 23andMe had genotyped more than one million people worldwide. That same year Wojcicki announced the release of the company's first genetics research-focused module developed with ResearchKit, an open-source software created by Apple Inc. for the iPhone. The new module enabled researchers to collect genetic information for their studies from 23andMe customers, who had the option of contributing their data to research studies. The development marked a major step forward in Wojcicki's effort to make the company's ever-growing database of genetic information available to scientists.
Job Titles:
- Founder
- Chief Data Scientist at UC Health. Director of Bakar Computational Health Sciences Institute and Professor of Pediatrics at UCSF.
- Chief Data Scientist for the University of California Health System
Atul Butte, MD, PhD, is the Chief Data Scientist for the University of California Health System comprising 17 health professional schools, 6 medical centers, and 10 hospitals. He is also the Priscilla Chan and Mark Zuckerberg Distinguished Professor of Pediatrics and inaugural Director of the Bakar Computational Health Sciences Institute at the University of California, San Francisco (UCSF).
Dr. Butte builds and uses translational bioinformatic tools to harness trillions of molecular, clinical, and epidemiological data points for application in cancer drug discovery, diagnostics, electronic medical records, and healthcare. Prior to joining UCSF, he was the Chief of the Division of Systems Medicine and Associate Professor of Pediatrics and by courtesy, Computer Science and Immunology and Rheumatology at Stanford University.
Having authored over 200 publications, Dr. Butte was elected into the National Academy of Medicine and recognized by the Obama Administration as a White House Champion of Change in Open Science for promoting science through publicly available data. He co-authored Microarrays for an Integrative Genomic s, one of the first books on microarray analysis.
Dr. Butte is a founder of three investor-backed data-driven companies: Personalis, providing medical genome sequencing services, Carmenta (acquired by Progenity), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. He is a principal investigator of the major programs the California Initiative to Advance Precision Medicine, implementing Governor Brown's vision to promote precision medicine in California, and ImmPort, the clinical and molecular data repository for the National Institute of Allergy and Infectious Diseases.
Dr. Butte received his B.A. in computer science from Brown University, his M.D. from Brown University, and his Ph.D. from Harvard Medical School and MIT. He has worked as a software engineer at Apple and Microsoft and trained in pediatrics and pediatric endocrinology at Boston Children's Hospital.
Job Titles:
- Professor of Surgery at Harvard University. Former CEO of Haven Healthcare.
Atul Gawande, MD, MPH, is a surgeon, writer, and public health leader. He is a surgeon at Brigham and Women's Hospital and a professor at Harvard Medical School and the Harvard T.H. Chan School of Public Health. He is the founder and chair of Ariadne Labs, a joint center for health systems innovation, and of Lifebox, a nonprofit organization making surgery safer globally. He is also chairman of Haven, where he was CEO from 2018 to 2020.
Atul has also been staff writer for The New Yorker magazine since 1998 and written four New York Times best selling books: Complications, Better, The Checklist Manifesto, and Being Mortal: Medicine and What Matters in the End. He is the winner of two National Magazine Awards, AcademyHealth's Impact Award for highest research impact on healthcare, a MacArthur Fellowship, and the Lewis Thomas Award for writing about science.
Caitlin Rivers, Ph.D., is an infectious disease epidemiologist, Senior Scholar at the Johns Hopkins Center for Health Security (JHCHS), and Assistant Professor in the Department of Environmental Health and Engineering at the Johns Hopkins Bloomberg School of Public Health (JHSPH). Her research focuses on improving public health preparedness and response, particularly by improving capabilities for "outbreak science" and infectious disease modeling to support public health decision making.
Prior to joining Johns Hopkins, Dr. Rivers worked as a civilian epidemiologist for the U.S. Army. She served as acting Branch Chief in the Disease Epidemiology Division, Chief Epidemiologist of the Health of the Force surveillance report product line, and manager of the Acute Respiratory Surveillance Program, which has run continuously for 50 years. As a Department of Defense Science, Mathematics, and Research Transformation (SMART) Scholar, she served as the senior epidemiologist on several outbreak investigations, including with the Special Operations community.
Dr. Rivers additionally participated in a National Science and Technology Council interagency working group aimed at bringing pandemic prediction and forecasting in capabilities into the federal government. She has been honored with the Department of the Army Achievement Medal for Civilian Service, JHCHS Emerging Leaders in Biosecurity Fellowship, and JHSPH Faculty Award for Excellence in U.S. Public Health Practice.
Dr. Rivers received her B.A. in anthropology from the University of New Hampshire and her M.P.H. in infectious diseases and Ph.D. in genetics, bioinformatics and computational biology from Virginia Tech, where she focused on computational epidemiology, particularly modeling emerging infectious diseases to support public health decision making. Her research concentrated on data related to outbreaks of avian influenza, MERS, and Ebola.
Job Titles:
- Professor of Immunotherapy at University of Pennsylvania.
- Richard W. Vague Professor
Carl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania.
He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston, 1979. He had graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978-79, and post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 - 1986. He is board certified in Internal Medicine and Medical Oncology. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The treatment has also now also been used with promising results to treat children with refractory acute lymphoblastic leukemia.
He has published more than 350 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012 and the American Academy of Arts and Sciences in 2014, the William B Coley award, the Richard V Smalley Memorial Award from the Society for Immunotherapy of Cancer, the AACR-CRI Lloyd J. Old Award in Cancer Immunology, the Philadelphia Award in 2012, the Taubman Prize for Excellence in Translational Medical Science in 2014 (shared w S. Grupp, B. Levine, D. Porter), the Paul Ehrlich and Ludwig Darmstaedter Prize (shared w J. Allison), the Novartis Prize in Immunology (shared w Z. Eshaar and S. Rosenberg), the Karl Landsteiner Memorial award, the Debrecen Award and a lifetime achievement award from the Leukemia and Lymphoma Society.
Job Titles:
- Member of the National Academy of Sciences
- Professor of Chemistry at Stanford University
Carolyn Bertozzi is a Nobel-Prize winning Professor of Chemistry at Stanford University and an Investigator at the Howard Hughes Medical institute. She coined the term "bioorthogonal chemistry" to describe chemical reactions that can take place within living cells and organisms. She has expanded this new field of chemistry to advance glycobiology technologies and biotherapeutics.
Her research spans the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars pertinent to human health and disease. Her lab develops technologies for imaging glycans and developing immuno-oncological diagnostics and therapeutics.
She is a founder of Lycia Therapeutics, OliLux Biosciences, Grace Science, InterVenn Biosciences, Palleon Pharmaceuticals, Enable Biosciences, and Redwood Bioscience.
Dr. Bertozzi is a member of the National Academy of Sciences, the National Academy of Inventors, the Institute of Medicine, and the American Academy of Arts and Sciences.
She was awarded the 2022 Nobel Prize in Chemistry. She was also the first woman to receive the Lemelson-MIT Prize. She has also been recognized with the Heinrich Wieland Prize, ACS Award in Pure Chemistry, and MacArthur Foundation Fellowship.
Dr. Bertozzi earned her B.A. in chemistry from Harvard University and Ph.D. in chemistry from the University of California, Berkeley, where she discovered that viruses can bind to sugars in the body. She completed her postdoctoral studies at the University of California, San Francisco.
Job Titles:
- CEO
- Founder
- Founder and CEO of Insitro. Pioneer of Machine Learning and Online Education.
Daphne Koller, Ph.D., is the founder and CEO of insitro, a data-driven company leveraging machine learning and high-throughput biology to transform the drug discovery and development process. She leads insitro's efforts to apply bioengineering technologies to create massive data sets and predictive models that accelerate target selection, design effective therapeutics, and inform clinical strategy.
Koller previously co-founded Coursera, an online education platform that partners with top universities and organizations to offer accessible courses to the public. She was the Chief Computing Officer at CalicoLabs, where she led the development of computational methods for analyzing biological data sets in order to better understand the process of aging.
She has been recognized as one of TIME's 100 Most Influential People, Newsweek's 10 Most Influential People, and Fast Company's Most Creative People. Among her other honors are the ACM Prize in Computing, MacArthur Foundation Fellowship, IJCAI Computers and Thought Award, Presidential Early Career Award for Scientists and Engineers (PECASE), and membership in the American Academy of Arts and Sciences and the National Academy of Engineering.
Koller received her B.Sc. and M.Sc. in mathematics and computer science from The Hebrew University of Jerusalem, and her Ph.D. in computer science from Stanford University. She completed her postdoctoral studies at the University of California, Berkeley. She later joined Stanford University as the Rajeev Motwani Professor of Computer Science, where she focused on modeling large, complicated decisions with lots of uncertainty, including using Bayesian networks to explore biomedical and genetic data sets.
David Baltimore, Ph.D., is the Robert A. Millikan Professor of Biology and former President of the California Institute of Technology (Caltech).
In 1975, Baltimore was awarded the Nobel Prize in Physiology or Medicine for his key discovery and application of reverse transcription in viruses, which contributed widely to the understanding of cancer, AIDS, and the molecular basis of the immune response. Reverse transcription was instrumental in the identification of human immunodeficiency virus (HIV) as the cause of AIDS, and reverse transcriptases subsequently became a successful therapeutic target for the disease, resulting in several HIV-suppression drugs.
He also devised the Baltimore classification system, a taxonomy that classifies viruses into seven groups according to their genome type and their method of replication. Baltimore currently studies control of inflammatory and immune responses, the roles of microRNAs in the immune system, and on the use of gene therapy methods to treat HIV and cancer. He heads the Joint Center for Translational Medicine, a Caltech and UCLA collaboration that aims to translate basic scientific discoveries into clinical realities.
One of the world's most influential biologists, Baltimore has influenced national science policy on issues including recombinant DNA research and the AIDS epidemic as the Founding Director of MIT's Whitehead Institute for Biomedical Research, Chair of the National Academy of Sciences committee on a National Strategy for AIDS, and Chair of the National Institutes of Health AIDS Vaccine Research Committee. He was also a member of the Independent Citizen's Oversight Committee to the California Institute for Regenerative Medicine and the Board of Directors for MedImmune and Cellerant. He helped found biotechnology companies Calimmune, Immune Design, and s2a Molecular, and now serves on the Board of Directors of Amgen, Regulus Therapeutics, and the Broad Foundation and Broad Institute.
Among his other honors are the National Medal of Science and membership of the National Academy of Sciences, the Institute of Medicine, the American Association for Cancer Research, the Royal Society, and the American Association for the Advancement of Science, where he served as President.
Baltimore obtained his B.A. in chemistry from Swarthmore College and his Ph.D. from Rockefeller University, where he returned to serve as a faculty member and President. He later entered a faculty role at MIT, where he began studying RNA viruses.
Job Titles:
- CEO and President of Cigna.
- Founder of the David and Sherry Cordani Family Foundation
David Cordani is the CEO and President of Cigna. He has spearheaded its transformation into a leading global health service company and is a prominent voice addressing key health challenges, such as the empowering of individuals to manage their own health, innovating new health delivery models focused on patients' health improvements, and partnering with physicians to focus on wellness, and improving clinical quality.
Cordani leads Cigna's global team in improving the health, well-being, and peace of mind for more than 160 million customer and patient relationships. Under his leadership, the company has significantly expanded its portfolio and led the industry as a partner-of-choice for collaboration with health care professionals and growing value-based care arrangements.
Cordani is the founder of The David and Sherry Cordani Family Foundation. He also serves on the General Mills Board of Directors, the U.S.-India Business Council Board of Directors, the U.S. Chamber of Commerce's U.S.-Korea Business Council as the Chairman, and the Board for America's Health Insurance Plans (AHIP) as the Chair.
He received his B.B.A. from Texas A&M University and his M.B.A. from the University of Hartford.
Job Titles:
- President of Gladstone Institutes. Former President of ISSCR. Professor of Pediatrics at UCSF.
Job Titles:
- Professor of Medicine and Engineering at the University of Southern California Keck School of Medicine
- Professor of Medicine and Engineering at USC.
Dr. David B. Agus is a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the founding CEO of USC's Lawrence J. Ellison Institute for Transformative Medicine. He is one of the world's leading physicians and the cofounder of several pioneering personalized medicine companies. Over the past twenty-five years he's received acclaim for his innovations in medicine and contributions to new technologies that will change how all of us maintain optimal health. He's also built a reputation for having a unique way of looking at the relationship of the human body to health and disease. As a contributor to CBS News, he comments on important health topics regularly on television.
Dr. Agus specializes in treating patients with advanced cancer. His clinical responsibilities include the development of clinical trials for new drugs and treatments for cancer, supported by the National Cancer Institute and other private foundations (he has no financial ties to pharmaceutical companies). He serves in leadership roles at the World Economic Forum, among other prestigious organizations, and is a recipient of the Ellis Island Medal of Honor. After earning his BA from Princeton University and medical degree from the University of Pennsylvania School of Medicine, he completed his medical residency training at Johns Hopkins Hospital, a research fellowship at the National Institutes of Health, and an oncology fellowship at the Memorial Sloan-Kettering Cancer Center.
Dr. Agus' first book, The End of Illness, was published in 2012 and is a New York Times #1 and international best seller, and subject of a PBS special. His second book, New York Times best-selling A Short Guide to a Long Life, was published January 2014, and his newest book The Lucky Years: How to thrive in the brave new world of health, also a New York Times bestseller was published in 2016. He is presently working on his fourth book, tentatively called Deep into Nature: What We Can Learn from the Tree of Life.
Dr. Emmanuelle Charpentier is the Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and Honorary Professor at Humboldt University. She is best known for her co-discovery of a molecular tool known as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, and was awarded the 2020 Nobel Prize in Chemistry along with her collaborator Dr. Jennifer Doudna for the development of a method for genome editing.
Dr. Charpentier has focused most of her scientific career on the understanding of fundamental mechanisms of diseases with a particular focus on infections caused by Gram-positive bacterial pathogens such as Listeria, staphylococci and streptococci. Her research on the CRISPR-Cas9 adaptive immune system in the human pathogen Streptococcus pyogenes and other bacterial species has laid the foundation for the development of CRISPR-Cas technology, a novel, highly versatile and specific genome editing and engineering technology that is revolutionizing life sciences research. CRISPR-Cas has opened whole new opportunities in biotechnologies and in biomedical gene therapies that are impacting society and humanity.
For her and her team's contributions to the CRISPR-Cas9 discovery, Dr. Charpentier has received numerous honors, decorations, prizes, awards and honorary doctorate degrees from Europe, Asia and North America. She is an elected member of national and international scientific academies including the Royal Swedish Academy of Sciences, European Academy of Sciences and Arts, and European Molecular Biology Organization (EMBO).
Dr. Charpentier co-founded CRISPR Therapeutics and ERS Genomics with the aim to develop the CRISPR-Cas genome engineering technology for biotechnological and biomedical applications.
Job Titles:
- Associate
- Chief Executive Officer
- CEO of Altos Labs
Dr. Hal Barron is Chief Executive Officer and Board Co-Chair of Alto Labs.
Previously, Dr. Barron was Chief Scientific Officer and President, R&D of GSK. He was responsible for all research and development of pipeline molecules as well as life-cycle management of approved medicines. He was also Executive Director of the GSK Board and a member of the Corporate Executive Team.
Prior to GSK, Dr. Barron was President, R&D at Calico (California Life Company) and Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.
Dr. Barron is an Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is a Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company and a member of the Advisory Board of Verily Life Sciences LLC, a subsidiary of Alphabet, Inc. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.
He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.
Dr. Barron has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.
Dr. Jennifer Doudna is best known for her co-discovery of a molecular tool known as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9. The 2012 discovery of CRISPR-Cas9 provided the foundation for gene editing, enabling researchers to make specific changes to DNA sequences in a way that was far more efficient and technically simpler than earlier methods. She was awarded the 2020 Nobel Prize in Chemistry along with her collaborator Dr. Emmanuelle Charpentier for the development of a method for genome editing.
Her co-discovery of CRISPR-Cas9 genetic engineering technology, with collaborator Emmanuelle Charpentier, changed human and agricultural genomics research forever. This genome-editing technology enables scientists to change or remove genes quickly, with a precision only dreamed of just a few years ago. Labs worldwide have re-directed the course of their research programs to incorporate this new tool, creating a CRISPR revolution with huge implications across biology and medicine. In addition to her scientific achievements and eminence, Dr. Doudna is also a leader in public discussion of the ethical and other implications of genome editing for human biology and societies, and advocates for thoughtful approaches to the development of policies around the use of CRISPR-Cas9.
Dr. Doudna is the Li Ka Shing Chancellor's Chair and a Professor in the Departments of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley. Her lab at UC Berkeley, the Doudna Lab, pursues a mechanistic understanding of fundamental biological processes involving RNA molecules. Dr. Doudna is also an investigator with the Howard Hughes Medical Institute, senior investigator at Gladstone Institutes, and the founder and President of the Innovative Genomics Institute. She is a co-founder of Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Mammoth Biosciences, and Scribe Therapeutics.
In addition to being recognized by TIME as one of the "100 Most Influential People" in 2015 and a runner-up for "Person of the Year" in 2016, Dr. Doudna has been honored with the Breakthrough Prize in Life Sciences (2015), the Japan Prize (2016), Kavli Prize (2018), the LUI Che Woo Welfare Betterment Prize (2019), and the Wolf Prize in Medicine (2020). She is the co-author of "A Crack in Creation," a personal account of her research and the societal and ethical implications of gene editing, and a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, the American Academy of Arts and Sciences, and a Foreign Member of the Royal Society.
Job Titles:
- Executive Vice President and Chief Patient Officer of Merck.
Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer of Merck, where she is responsible for a broad portfolio focused on patient engagement, strategic communications, global public policy, population health and corporate responsibility. She addresses critical issues such as affordable access to therapies, health policies that promote and sustain innovation of new medicines and vaccines, and maternal health through the Merck for Mothers program, which aims to help meet the United Nations' Sustainable Development Goal to reduce maternal mortality. She was the former President of Merck Vaccines.
Previously, Dr. Gerberding was Director of the U.S. Centers for Disease Control and Prevention (CDC), where she led the agency response to more than 40 public health crises including anthrax, SARS, bird flu, food-borne outbreaks, and natural disasters. She joined the CDC as Director of the Division of Healthcare Quality Promotion to develop the agency's patient safety initiatives to prevent infections, antimicrobial resistance, and medical errors.
In addition to her role as Executive Sponsor of the Merck Women's Network, Dr. Gerberding currently serves on the Boards of Biotechnology Innovation Organization (BIO), Cerner Corporation, and the MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries. She is a member of the National Academy of Medicine and a fellow of the Infectious Diseases Society of America and the American College of Physicians.
Dr. Gerberding has received more than 50 awards and honors, including the U.S. Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks, and eyeforpharma's Lifetime Achievement Award. She was named one of TIME's 100 Most Influential People, Forbes' 100 Most Powerful Women, and the Healthcare Businesswomen Association's Woman of the Year.
Dr. Gerberding received her B.A. in chemistry biology and M.D. from Case Western Reserve University, and her M.P.H. from the University of California, Berkeley. She completed her internship and residency in internal medicine and fellowship in clinical pharmacology and infectious diseases at the University of California, San Francisco, where she served during the HIV/AIDS crisis and directed the Prevention Epicenter, and is currently an Adjunct Associate Professor of Medicine. She is board certified in Internal Medicine and Infectious Diseases.
Job Titles:
- Founder and Director of Scripps Research Translational Institute.
- Founder and Director of the Scripps Research Translational Institute
Eric Topol is the Founder and Director of the Scripps Research Translational Institute, Professor, Molecular Medicine, and Executive Vice-President of Scripps Research. As a researcher, he has published over 1,200 peer-reviewed articles, with more than 250,000 citations, elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine. His principal scientific focus has been on the genomic and digital tools to individualize medicine.
In 2016, Topol was awarded a $207 million grant from the National Institutes of Health (NIH) to lead a significant part of the Precision Medicine (All of Us) Initiative, a prospective research program enrolling 1 million diverse participants in the US. This is in addition to his role as principal investigator for a flagship $35 million NIH grant to promote innovation in medicine. Prior to coming to Scripps in 2007, he led the Cleveland Clinic to become the #1 center for heart care and was the founder of a new medical school there. He has been voted as the #1 most Influential physician leader in the United States in a national poll conducted by Modern Healthcare. Besides editing several textbooks, he has published 3 bestseller books on the future of medicine: The Creative Destruction of Medicine and The Patient Will See You Now and latest Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again in 2019. Topol was commissioned by the UK in 2018-2019 to lead planning for the National Health Service's integration of AI and new technologies.
Job Titles:
- Founder and CEO of Curie Co. Enzyme Engineering Pioneer.
Frances Arnold is a chemical engineer who was awarded the 2018 Nobel Prize for Chemistry for her work on directed evolution of enzymes.
Arnold received a bachelor's degree in mechanical and aerospace engineering from Princeton University and a doctorate in chemical engineering from the University of California, Berkeley. She spent a year as a postdoctoral fellow at Berkeley before arriving at the California Institute of Technology (Caltech) as a visiting associate. She was soon promoted to assistant professor and has remained at Caltech ever since, rising to full professor within a decade. She was named to an endowed chair in 2000.
At Caltech, Dr. Arnold pioneered methods of "directed evolution" to create new proteins not found in nature. At first, she followed established practice, attempting to induce specific mutations in DNA molecules to achieve predetermined results. She came to realize that this process could expend decades of work without achieving any significant results. Dr. Arnold decided to use a different approach, that of evolution. She and her coworkers extended the technique of directed enzyme evolution to change enzymes for reactions that no enzyme had catalyzed before. They also evolved enzymes to make substances with bonds that do not occur in biology. Publication of Dr. Arnold's work in 1993 created a sensation in the scientific community and placed her at the forefront of her field.
Her laboratory has generated novel and useful enzymes and organisms for applications in medicine, neurobiology, chemical synthesis, and alternative energy. She and her team have constructed entire synthetic families of enzymes and other proteins to study the relationship of structure and function outside of the normal patterns of natural selection. Her work has led to the production of enzymes that function in airless environments, enabling the production of biofuels without reliance on expensive air-circulating equipment. She co-founded the biofuel company Gevo in 2005 and a second company, Provivi, in 2013 to develop green biocatalytic processes for agricultural and specialty chemicals.
In addition to the Nobel Prize, Dr. Arnold received the Charles Stark Draper Prize and the National Medal of Technology and Innovation.
Job Titles:
- CEO and President of Illumina.
Francis deSouza is the CEO and President of Illumina, a global leader in DNA sequencing and array-based technologies. Under his leadership, Illumina is driving adoption of genomic sequencing to unlock the power of the genome and improve human health. DeSouza is currently responsible for directing all aspects of company strategy, planning and operations, and previously led the company's business units and core functions responsible for envisioning, developing, and producing its products.
Prior to joining Illumina, deSouza held the roles of President, Products and Services, and Senior Vice President, Enterprise Security Group, at Symantec, where he was responsible for driving the vision for the company's marketing-leading portfolio. He previously founded the technology companies Flash Communications (acquired by Microsoft) and IMlogic (acquired by Symantec).
DeSouza has been named one of Glassdoor's Top 100 CEOs, Silicon Valley Business Journal's Silicon Valley 40 Under 40, Fast Company's Fast 50 Champion of Innovation, and a Fortune Businessperson of the Year. He is currently a member of the Board of Directors of The Walt Disney Corporation.
He earned his B.S. and M.S. in electrical engineering and computer science from MIT before later joining IBM, Microsoft, and Symantec.
Job Titles:
- Physician
- Acting Science Advisor to President
- Acting Science Advisor to the President, Former Director of the National Institutes of Health.
Francis S. Collins, M.D., Ph.D. is Acting Science Advisor to President Joe Biden. He was previously appointed the 16th Director of the National Institutes of Health (NIH) by President Barack Obama and confirmed by the Senate. He was sworn in on August 17, 2009. On June 6, 2017, President Donald Trump announced his selection of Dr. Collins to continue to serve as the NIH Director. In this role, Dr. Collins oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research.
Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at NIH from 1993-2008.
Before coming to NIH, Dr. Collins was a Howard Hughes Medical Institute investigator at the University of Michigan. He is an elected member of the National Academy of Medicine and the National Academy of Sciences, was awarded the Presidential Medal of Freedom in November 2007, and received the National Medal of Science in 2009. In 2020, he was elected as a Foreign Member of the Royal Society (UK) and was also named the 50th winner of the Templeton Prize, which celebrates scientific and spiritual curiosity.
Job Titles:
- Professor of Genetics
- Professor of Genetics at Harvard Medical School
- Professor of Health Sciences and Technology
George Church is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center and Director of the National Institutes of Health Center of Excellence in Genomic Science. He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering.
Church leads Synthetic Biology at the Wyss Institute, where he oversees the directed evolution of molecules, polymers, and whole genomes to create new tools with applications in regenerative medicine and bio-production of chemicals. Among his recent work at the Wyss is development of a technology for synthesizing whole genes, and engineering whole genomes, far faster, more accurate, and less costly than current methods. George is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. In 1984, he developed the first direct genomic sequencing method, which resulted in the first genome sequence (the human pathogen, H. pylori). He helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. George invented the broadly applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers. His many innovations have been the basis for a number of companies including Editas (Gene therapy); Gen9bio (Synthetic DNA); and Veritas Genetics (full human genome sequencing).
Church earned his PhD in biochemistry and molecular biology from Harvard University.
Job Titles:
- CEO and Chairman of Bristol Myers Squibb.
- CEO and Chairman of the Board of Bristol Myers Squibb
Giovanni Caforio is the CEO and Chairman of the Board of Bristol Myers Squibb (BMS). Caforio leads the company's focus on researching and developing transformational medicines, which includes a leading portfolio of cancer immunotherapies. Under his leadership, BMS is evolving its operating model in order to increase speed and competitiveness.
Caforio has made significant contributions to improving BMS's global strategic focus and operational performance. As the former Chief Operating Officer, Executive Vice President, and Chief Commercial Officer, he led the transformation of the fully integrated worldwide commercial organization and the companywide functions of enterprise services and global manufacturing and supply. He also helped establish BMS as a leader in immuno-oncology as President of US Pharmaceuticals and Senior Vice President of Global Oncology and Immunology.
Prior to joining BMS, he received his M.D. from the University of Rome and held research and marketing leadership roles at Abbott Laboratories. He is currently a member of the Board of Trustees of Hun School of Princeton, the Business Roundtable, CEO Roundtable on Cancer, the Pharmaceutical Research and Manufacturers of America (PhRMA), and The Prium.
Job Titles:
- Founder of JCVI, Co - Founder of Synthetic Genomics, Inc. and Human Longevity, Inc.
J. Craig Venter is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. Dr. Venter is Founder, Chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization with approximately 200 scientists and staff dedicated to human, microbial, plant, synthetic and environmental genomic research, and the exploration of social and ethical issues in genomics.
Venter also is a co-founder of Synthetic Genomics, Inc. (SGI) and Human Longevity, Inc. (HLI). SGI is a privately held company developing products and solutions including sustainable bio-fuels, vaccines, biotherapeutics and transplantable organs. HLI is a genomic-based, health intelligence company empowering proactive healthcare.
Venter began his formal education after a tour of duty as a Navy Corpsman in Vietnam from 1967 to 1968. After earning both a Bachelor of Science in Biochemistry and a PhD in Physiology and Pharmacology from the University of California at San Diego, he was appointed professor at the State University of New York at Buffalo and the Roswell Park Cancer Institute. In 1984, he moved to the National Institutes of Health campus where he developed Expressed Sequence Tags or ESTs, a revolutionary new strategy for rapid gene discovery.
In 1992, Venter founded The Institute for Genomic Research (TIGR, now part of JCVI), a not-for-profit research institute, where in 1995 he and his team decoded the genome of the first free-living organism, the bacterium Haemophilus influenzae, using his new whole genome shotgun technique.
In 1998, Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed. This research culminated with the February 2001 publication of the human genome in the journal, Science. He and his team at Celera also sequenced the fruit fly, mouse and rat genomes.
Venter and his team at JCVI continue to blaze new trails in genomics. They have sequenced and analyzed hundreds of genomes, and have published numerous important papers covering such areas as environmental genomics, the first complete diploid human genome, and the groundbreaking advance in creating the first self-replicating bacterial cell constructed entirely with synthetic DNA.
Venter is one of the most frequently cited scientists, and the author of more than 280 research articles. He is also the recipient of numerous honorary degrees, public honors, and scientific awards, including the 2008 United States National Medal of Science, the 2002 Gairdner Foundation International Award, the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize and the King Faisal International Award for Science. Venter is a member of numerous prestigious scientific organizations including the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Microbiology.
Job Titles:
- Director of the Parker Institute for Cancer Research
Allison is also the Director of the Parker Institute for Cancer Research and the Cancer Research Institute. Among his discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models.
Job Titles:
- President and Former Chief Medical Officer at Livongo.
- President and Former Chief Medical Officer of Livongo
Jennifer Schneider is the President and former Chief Medical Officer of Livongo, a digital health company empowering people with chronic conditions to live better and healthier lives. She is responsible for the company's product, data science, software engineering, marketing, and clinical operations. As CMO, she led Livongo's strategic clinical product vision, clinical trials, and certified diabetes educators and coaches.
Prior to joining Livongo, Dr. Schneider held key leadership roles at Castlight Health, most recently leading product innovation as its Chief Medical Officer. She also served in the provider setting as a Health Outcomes Researcher and Chief Resident at Stanford University, and practiced medicine as an attending physician at Stanford University, the VA Palo Alto Health Care System, and Kaiser Permanente.
Dr. Schneider earned her bachelor's degree from the College of the Holy Cross, her M.D. from Johns Hopkins School of Medicine, and her M.S. in health services research from Stanford University, before completing her internal medicine residency at Stanford University Hospital. She was recently named one of Modern Healthcare's 50 Most Influential Clinical Executives.
Job Titles:
- Co - Founder and Chief Medical and Scientific Officer of Verily.
Job Titles:
- Co - Founder
- Chief Innovation Officer of Boston Children 's Hospital
John Brownstein is the Chief Innovation Officer of Boston Children's Hospital and Professor of Pediatrics at Harvard Medical School. At Boston Children's Hospital, he directs the Computational Epidemiology Lab and the Innovation and Digital Health Accelerator.
A trained epidemiologist, Brownstein uses emerging technologies to help clarify patterns of influenza epidemics and pandemics, and promote public health interventions including vaccination, quarantine, and travel restrictions. He pioneered the use of digital data sources to advance understanding of population health, or "digital epidemiology." He has been at the forefront of the development and application of data mining and citizen science to public health.
Brownstein is the co-founder of digital health companies Circulation and Epidemico. He also leads the development of public health tools HealthMap, an internet-based surveillance system that tracks emerging infectious disease threats, Vaccine Finder, and MedWatcher. Brownstein serves as a healthcare advisor to Uber.
He also plays advisory roles to numerous agencies on real-time public health surveillance including the World Health Organization, Institute of Medicine, the U.S. Departments of Health and Human Services and Homeland Security, and the White House. In addition to being recognized by the National Library of Congress and the Smithsonian for his work, Brownstein has received the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the U.S. government to outstanding scientists, and the Lagrange Prize for international achievements in complexity sciences.
Brownstein received his bachelor's degree in biology from McGill University and Ph.D. in epidemiology from Yale University. He has authored over 200 peer-reviewed articles on epidemiology and digital and public health.
Job Titles:
- Co - Founder and Chief Science Officer of Variant Bio.
- Co - Founder and CSO at Variant
Kaja Wasik is the co-founder and CSO at Variant Bio, of a global platform that leverages the enormous power of human genetic diversity to discover a new generation of therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits.
Kaja has spent her career developing novel sequencing platforms and bringing them to market. Before joining Variant Bio she was a co-founder and CSO at Gencove, one of the first companies to provide commercial, low pass whole-genome sequencing. Kaja completed her PhD in molecular biology at Cold Spring Harbor Laboratory and postdoctoral training at the New York Genome Center.
Job Titles:
- CEO and President of Mount Sinai.
- CEO and President of the Mount Sinai Health System
- Member of the Institute of Medicine
- Professor, and Chair of Mount Sinai 's Department of Psychiatry
Kenneth L. Davis, M.D., is the CEO and President of the Mount Sinai Health System, the largest academic medical system in New York City. Dr. Davis leads the efforts that have transformed the Mount Sinai Health System into one of the nation's largest integrated health systems, with $8 billion in revenue, 42,000 employees, eight hospitals, and an extensive ambulatory platform. During his tenure, he helped launch what has been characterized as one of the largest financial turnarounds in academic medicine, placing the institution on a trajectory of dramatic growth of both scope and ambition, entering a new era of innovation in collaborative research, education, and clinical care.
As a neurobiologist, Dean, Professor, and Chair of Mount Sinai's Department of Psychiatry, Dr. Davis conducted pioneering research that led the FDA to approve four of the first five drugs for the treatment of Alzheimer's disease and to a revolutionary understanding of white matter, oligodendrocytes, and myelin in the pathophysiology of schizophrenia, opening an entirely new approach to the treatment of the neurodegenerative disease. He developed the widely used Alzheimer's Disease Assessment Scale and made significant contributions to schizophrenia research.
Dr. Davis was also the Director of the Alzheimer's Disease Research Center, the Schizophrenia Biological Research Center, the Silvio Conte Neuroscience Center, and the Seaver Autism Center for Research and Treatment, as well as Chief of the Department of Psychiatry at the Bronx's Veterans Affairs (VA) Medical Center.
One of the most highly cited researchers in the field of brain diseases, Dr. Davis is an elected member of the Institute of Medicine of the National Academy of Sciences and has been recognized by the Alzheimer's Association, the Society of Biological Psychiatry, and the American Psychiatric Association. He was also awarded the George H. W. Bush Lifetime of Leadership Award from Yale University, where he earned his bachelor's degree before obtaining his M.D. from the Icahn School of Medicine.
Kryzysztof Chylinski completed his doctoral studies at the University of Vienna, in the laboratory of Emmanuelle Charpentier and Renée Schroeder at Max F. Perutz Laboratories, where, from 2008, he worked on RNA binding proteins in Streptococcus pyogenes, but soon focused on CRISPR-Cas type II, which is a bacterial immune tool. CRISPR-Cas eventually became the topic of his doctorate.
Research conducted with colleagues from the laboratory on molecular mechanisms as well as the differentiation and evolution of type II CRISPR resulted in publications, among others in Nature and Science. These mechanisms also began to attract the attention of other researchers after Chylinski and colleagues proposed and described ways to use CRISPR type II as genome editing tools (now known as CRISPR / Cas9). From 2014, Chylinski continued his research on CRISPR / Cas9 together with Peggy Stolt-Bergner, together they created the CRISPR-Lab
Chylinski continued his work on CRISPR-Cas9 at the Vienna BioCenter Core Facilities (VBCF) until 2020. He has received the Vienna BioCenter PhD award, the Bank Austria Research Award, and the Award of Excellence from the Austrian Federal government for his critical contributions.
Job Titles:
- Head of Genome Engineering Services at Vienna BioCenter.
Job Titles:
- Co - Founder, CEO, and President of Regeneron.
Leonard S. Schleifer, M.D., Ph.D., is the co-founder, CEO, and President of Regeneron, a leading biotechnology company inventing medicines for people with serious diseases. Under his leadership, Regeneron has developed a portfolio of seven FDA-approved treatments and continues to develop numerous product candidates. The company's medicines and pipeline focus on eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. He previously served as Chairman of the Board.
Dr. Schleifer has been recognized as one of Barron's Best CEOs and as an Ernst & Young Entrepreneur of the Year. He earned his B.S. from Cornell University, and his M.D. and Ph.D. in pharmacology from the University of Virginia, where he studied under pharmacologist Alfred G. Gilman. He is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology, and worked as a practicing neurologist before founding Regeneron.
Job Titles:
- CEO and President of Intermountain Healthcare.
Marc Harrison, MD, is the CEO and President of Intermountain Healthcare, the largest healthcare provider in the Intermountain West consisting of 23 hospitals, more than 185 clinics, a medical group with 1,500 multi-specialty doctors and caregivers, and one of Utah's largest health insurers. He leads the creation and execution of Intermountain's strategy to transform healthcare through best clinical and operational practices.
A specialist in pediatric critical care, Dr. Harrison developed and implemented international strategy as the Chief of International Business Development at Cleveland Clinic, and oversaw the establishment of 12 institutes, five centers of excellence, and more than 30 medical and surgical specialities as the CEO of Cleveland Clinic Abu Dhabi. His previous roles also included Chief Medical Operations Officer and Chairman of Pediatric Critical Care.
Dr. Harrison was named one of Fortune Magazine's Top 50 World's Greatest Leaders as well as Modern Healthcare's Most Influential Physician Executives and Leaders, and 100 Most Influential People in Healthcare. He is a fellow of the American Academy of Pediatrics and the Society of Critical Care Medicine.
Dr. Harrison obtained his B.A. in psychology from Haverford College, his M.D. from Dartmouth Medical School, his M.M.M. from Carnegie Mellon University, and a certificate in Managing Healthcare Delivery from Harvard Business School. He completed a residency and fellowship at the University of Utah School of Medicine and worked primarily in the critical care units of Intermountain's Primary Children's Hospital.
Job Titles:
- Fellow of the the American Geophysical Union
- President of the National Academy of Sciences.
Marcia McNutt is the President of the National Academy of Sciences and Chair of the National Research Council. Previously, she served as the Editor-in-Chief of the peer-reviewed journal Science and Director of the U.S. Geological Survey (USGS), where she coordinated the response to a number of ecological disasters, including the Deepwater Horizon oil spill.
As the former President and CEO of the Monterey Bay Aquarium Research Institute, McNutt led the institution in its development of biological and chemical sensors for remote ocean deployment, installation of the first deep-sea cabled observatory in U.S. waters, and advancement of the integration of artificial intelligence into autonomous underwater vehicles for undersea missions.
A trained geophysicist, McNutt studied marine geophysics with a focus on the dynamics of the earth's upper mantle and lithosphere on geologic time scales. She held the title of E.A. Griswold Professor of Geophysics at MIT and directed the MIT-WHOI Joint Program in Oceanography/Applied Ocean Science and Engineering. She is a veteran of more than a dozen deep-sea expeditions.
McNutt is a fellow of the the American Geophysical Union, of which she was President; the Geological Society of America; American Association for the Advancement of Science; and the International Association of Geodesy. She is a member of the American Academy of Arts and Sciences and the American Philosophical Society.
She has been awarded the U.S. Coast Guard's Meritorious Service Medal and the Maurice Ewing Medal as well as honorary doctoral degrees from Boston University, Worcester Polytechnic Institute, the University of Minnesota, and Colorado College.
McNutt earned her B.A. in physics from Colorado College and her Ph.D. in earth sciences from the Scripps Institution of Oceanography, where she currently holds a visiting appointment.
Job Titles:
- CEO and Co - Founder of Oscar Health.
Mario Schlosser is the CEO and co-founder of Oscar, a health-insurance start-up that is using technology, design, and data to help humanize and simplify healthcare. Previously, he co-founded the largest social gaming company in Latin America, where he led the company's analytics and game design practices.
At Bridgewater Associates, Mario developed analytical trading models as a Senior Investment Associate. Prior to Bridgewater, he worked as a consultant for McKinsey & Company in Europe, the U.S. and Brazil. As a visiting scholar at Stanford University, Mario wrote and co-authored 10 computer science publications, including one of the most-cited computer science papers published in the past decade, in which he developed an algorithm to securely compute trust in randomized networks.
He holds a degree in computer science with highest distinction from the University of Hannover in Germany and an MBA from Harvard Business School.
Job Titles:
- Assistant Professor
- Assistant Professor of Biochemistry at the University of Zurich, Switzerland.
Martin Jinek is a Tenure-Track Assistant Professor in the Department of Biochemistry at the University of Zurich, Switzerland. His research is focused on protein-RNA interactions and macromolecular complexes involved in post-transcriptional regulation of gene expression or in genome defense pathways such as CRISPR-Cas. In his studies, Dr Jinek uses biochemical and structural approaches to investigate these processes at the atomic level.
Originally from the Czech Republic, Jinek studied Natural Sciences at the University of Cambridge (UK). In 2006, he received his PhD from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, where he carried out his doctoral research in the laboratory of Professor Elena Conti. He then moved to the University of California at Berkeley for postdoctoral research with Professor Jennifer Doudna, where his work made fundamental contributions towards developing the CRISPR-Cas9 system into a powerful genome editing technology.
In 2013, Jinek set up his independent research group in Zurich and was awarded a European Research Council (ERC) Starting Grant. In further recognition of his work, Martin Jinek has received the EMBL John Kendrew Young Scientist Award (2014) and the Friedrich Miescher Award of the Swiss Society for Molecular and Cellular Biosciences (2015).
Job Titles:
- Director at Gladstone Institutes. Professor of Medicine at UCSF.
- Director of the Gladstone Institute of Virology
Melanie Ott is the Director of the Gladstone Institute of Virology and a Professor of Medicine at the University of California, San Francisco (UCSF).
She studies the molecular mechanisms of viral pathogenesis with a focus on HIV-1 and Hepatitis C Virus. Specifically, she is investigating interactions between the viruses and their target cells to identify targets for novel therapeutics.
Ott is the recipient of the MERIT Award and Avant-Garde Award from the National Institutes of Health and the Chancellor Award for Public Service from UCSF. She is an elected member of the American Academy of Microbiology and Association of American Physicians.
She obtained her M.D. from the University of Frankfurt and her Ph.D. in molecular medicine from the Elmezzi Graduate School Of Molecular Medicine. A trained neurologist, she pivoted to virology during the AIDS crisis.
Job Titles:
- Chief Scientific Officer of Platform Research at Moderna.
Melissa Moore is a biochemist and molecular biologist recognized for her work in eukaryotic RNA processing and metabolism, and is the Chief Scientific Officer of Moore was born and raised in New Market, Virginia. She graduated from the College of William and Mary in 1984 with a BS in Chemistry and Biology, and earned her PhD in Biological Chemistry from the Massachusetts Institute of Technology (MIT) in 1989. Following a Helen Hay Whitney Postdoctoral Fellowship at the MIT Center for Cancer Research, Moore joined the Brandeis University faculty in 1994, where she was named a Searle Scholar and Packard Fellow. In 2007, Moore moved to the University of Massachusetts Medical School (UMMS), where she served as a founding co-director of the RNA Therapeutics Institute and held the Eleanor Eustis Farrington Chair of Cancer Research.
In 2011, Moore received the ASBMB William C. Rose Award for distinguished mentorship. Following a nineteen-year run as an HHMI Investigator (1997-2016), Moore resigned from HHMI to become the Chief Scientific Officer of the mRNA Research Platform at Moderna Therapeutics in Cambridge, MA. Moore maintains her academic affiliation with UMMS as a part-time faculty member.
Job Titles:
- CEO and President of BIO.
- CEO and President of the Biotechnology Innovation Organization
Michelle McMurry-Heath is the CEO and President of the Biotechnology Innovation Organization (BIO), the world's largest biotechnology advocacy group representing 1,000 life science companies and organizations from 30 countries and supporting scientific breakthroughs that improve human health, environmental stewardship, and sustainable agriculture.
A medical doctor and molecular immunologist by training, McMurry-Heath now focuses on broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge innovation.
Previously, McMurry-Heath held numerous senior roles at Johnson & Johnson as the Vice President of External Innovation, Executive Director of Scientific Partnerships for JLABS@DC, Worldwide Vice President of Regulatory and Clinical Affairs, and Global Head of Evidence Generation.
She also led science policy development as the Associate Science Director of the U.S. Food and Drug Administration's Center for Devices and Radiological Health, where she championed clinical trial evolution, the use of real-world evidence in product evaluation, and the patient voice in health research. As the Founding Director of the Aspen Institute's Health, Biomedical Science, and Society Policy Program, McMurry-Heath promoted personalized medicine and bolstered international preparation for pandemic disease threats. She also drafted legislation to protect the U.S. from biological attacks as Senator Joe Lieberman's top legislative aide for science and health.
After obtaining her B.A. in biochemistry and molecular biology from Harvard University, McMurry-Heath became the first African-American to receive her M.D. and Ph.D. upon graduation from the Duke Medical Scientist Training Program.
Job Titles:
- Senior Investigator at Gladstone Institutes. Professor of Cellular Molecular Pharmacology at UCSF.
Job Titles:
- Cofounder and CEO of Color Genomics.
Job Titles:
- Professor of Organismic and Evolutionary Biology at Harvard University. Principal Investigator at Sabeti Lab. Member of Broad Institute.
Job Titles:
- CEO and President of Stanford Children 's Health.
Job Titles:
- Founder and CEO of Girls Who Code.
Job Titles:
- CEO and Chairman of Amgen.
Job Titles:
- CEO of CRISPR Therapeutics
Job Titles:
- Co - Founder and CEO of MicroByre.
Job Titles:
- CEO at Harbinger Health, CEO - Partner at Flagship Pioneering, Former FDA Commissioner.
Job Titles:
- Dean for Cancer Innovation and Chief of Pediatric Oncology at Icahn School of Medicine at Mount Sinai.
Job Titles:
- Senior Investigator at Gladstone Institutes. Professor of Bioengineering at UCSF.
Job Titles:
- Professor of Vaccine and Infectious Disease at Fred Hutch. Professor of Genome Sciences and Epidemiology at the University of Washington.